According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “
A number of other research analysts have also recently issued reports on SYN. FBR & Co reiterated a buy rating on shares of Synthetic Biologics in a research note on Friday, August 5th. BTIG Research initiated coverage on shares of Synthetic Biologics in a research note on Thursday, August 25th. They issued a buy rating and a $5.00 target price for the company. Finally, Griffin Securities set a $5.80 target price on shares of Synthetic Biologics and gave the company a buy rating in a research note on Wednesday, August 31st.
Shares of Synthetic Biologics (NYSE:SYN) opened at 1.58 on Wednesday. Synthetic Biologics has a 1-year low of $0.93 and a 1-year high of $3.09. The company’s market capitalization is $144.21 million. The stock’s 50 day moving average price is $1.69 and its 200 day moving average price is $1.92.
Synthetic Biologics (NYSE:SYN) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. Analysts expect that Synthetic Biologics will post ($0.39) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the company. KCG Holdings Inc. acquired a new stake in Synthetic Biologics during the second quarter worth approximately $106,000. Rhumbline Advisers acquired a new stake in Synthetic Biologics during the second quarter worth approximately $126,000. Schwab Charles Investment Management Inc. acquired a new stake in Synthetic Biologics during the second quarter worth approximately $213,000. Teachers Advisors Inc. acquired a new stake in Synthetic Biologics during the second quarter worth approximately $216,000. Finally, BlackRock Investment Management LLC raised its stake in Synthetic Biologics by 2,517.2% in the second quarter. BlackRock Investment Management LLC now owns 282,158 shares of the company’s stock worth $508,000 after buying an additional 271,377 shares in the last quarter.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.